New G-CSF agonists for neutropenia therapy

Area of Science:

• Hematology
• Pharmacology
• Oncology

Background:

• Granulocyte colony-stimulating factor (G-CSF), including filgrastim and pegfilgrastim, is crucial for managing neutropenia in various conditions.
• G-CSF aids neutrophil count restoration, reduces infection risk, and is vital for stem cell mobilization in transplantation.

Purpose of the Study:

• To review the therapeutic applications, cost-effectiveness, and disease impact of G-CSF.
• To examine the development of G-CSF biosimilars and emerging next-generation therapies.

Main Methods:

• Literature review of G-CSF's therapeutic use.
• Analysis of cost-effectiveness and disease impact data.
• Evaluation of biosimilar development and future G-CSF alternatives.

Main Results:

• G-CSF has improved outcomes for congenital neutropenias, but its cost-effectiveness and survival impact in chemotherapy-induced neutropenia remain under investigation.
• New G-CSF biosimilars are expected to enhance cost-effectiveness, though none show superior efficacy to existing G-CSFs.
• Preclinical second-generation compounds offer potential alternatives, but significant therapeutic advances require greater reduction in neutropenia depth and duration.

Conclusions:

• G-CSF is a valuable therapeutic agent, with ongoing developments in biosimilars and novel compounds aiming to improve treatment paradigms.
• Further research is needed to clarify the cost-effectiveness and survival benefits of G-CSF in chemotherapy-associated neutropenia.
• Future advancements in neutropenia management may involve next-generation therapies offering superior efficacy over current G-CSF treatments.